Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer
Authors:
- L. RachedLRL. Rached
- F. Peyre-PradatFPF. Peyre-Pradat
- M. SpottiMSM. Spotti
- C. BaldiniCBC. Baldini
- A. LaparraALA. Laparra
- O. LambotteOLO. Lambotte
- M. SakkalMSM. Sakkal
- A. PerretAPA. Perret
- A. ViansoneAVA. Viansone
- S. MichielsSMS. Michiels
- S. DelalogeSDS. Delaloge
- B. PistilliBPB. Pistilli
Open Access
- 8 August 2024
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 5
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsCancer Treatment Reviews, 2024
- Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysisBritish Journal of Cancer, 2023
- Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?Current Treatment Options in Oncology, 2023
- Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future ApproachesCurrent Treatment Options in Oncology, 2023
- Tumor-associated neutrophils and neutrophil-targeted cancer therapiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trialAnnals of Oncology, 2020
- Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 studyAnnals of Oncology, 2020
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and StrategiesImmunity, 2018
- Immunological hallmarks of stromal cells in the tumour microenvironmentNature Reviews Immunology, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014